Therefore, we selected AKR1B10 and SPP1 co-sensitive drugs TGX-221 as a possible therapy to inhibit or delay the progression of NAFLD and improve the prognosis of NAFLD-HCC. Here, SPP1 is linked to hepatocellular carcinoma.